Making Successful 212Pb-Targeted Alpha Therapy a Reality
Time: 11:00 am
day: Day Two ESC AM
Details:
- Seeking to develop a new generation of targeted therapies against cancer, based on the unique properties of 212Pb
- Exploring the multi-asset portfolio, including two compounds in clinical development and a diverse pipeline
- Sharing more about AlphaMedixTM receiving Breakthrough Therapy Designation by the FDA
